Verastem Oncology Announces Two-Year Median Follow-Up Data on AVMAPKI® FAKZYNJA® Combination Therapy (avutometinib capsules; defactinib tablets) in Recurrent Low-Grade Serous Ovarian Cancer at the S
Go back to Verastem Oncology Announces Two-Year Median Follow-Up Data on AVMAPKI® FAKZYNJA® Combination Therapy (avutometinib capsules; defactinib tablets) in Recurrent Low-Grade Serous Ovarian Cancer at the S| VERASTEM SHS (NASDAQ: VSTM) | Delayed: 4.21 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $4.21 | 52 Week High | $2.43 | |||
| Open | $4.21 | 52 Week Low | $1.05 | |||
| Day High | $4.21 | P/E | N/A | |||
| Day Low | $4.21 | EPS | $-1.79 | |||
| Volume | 23,076 | |||||
